User:Mr. Ibrahem/Tofacitinib

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Tofacitinib
Clinical data
Trade namesXeljanz, Jaquinus, Tofacinix, Others
Other namesCP-690550
AHFS/Drugs.comMonograph
MedlinePlusa613025
License data
Pregnancy
category
Routes of
administration		By mouth (tablets)
Drug classJanus kinase (JAK) inhibitor and disease-modifying antirheumatic drug (DMARD)[2]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[3][4]
  • US: ℞-only[5]
  • EU: Rx-only[6]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability74%
Protein binding40%
MetabolismLiver (via CYP3A4 and CYP2C19)
Elimination half-life3 hours
ExcretionUrine
Identifiers
  • 3-[(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
Chemical and physical data
FormulaC16H20N6O
Molar mass312.377 g·mol−1
3D model (JSmol)
  • CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
  • InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
  • Key:UJLAWZDWDVHWOW-YPMHNXCESA-N

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ulcerative colitis.[2] It is used when other treatments are not effective.[6] It is taken by mouth.[2]

Common side effects include diarrhea, headache, and high blood pressure.[2] Serious side effects may include infections, cancer, angioedema, and pulmonary embolism.[2] There are concerns that higher doses may increase the risk of death.[2] Use in pregnancy may harm the baby.[7] It is a janus kinase (JAK) inhibitor.[2]

Tofacitinib was approved for medical use in the United States in 2012 and Europe in 2017.[2][6] In the United Kingdom it costs the NHS about £690 for 4 weeks of treatment at 5 mg twice per day as of 2021.[8] This amount in the United States costs about 4,600 USD.[9]

References[edit]

  1. ^ a b "Tofacitinib Use During Pregnancy". Drugs.com. 15 April 2020. Archived from the original on 29 November 2020. Retrieved 23 October 2020.
  2. ^ a b c d e f g h i j "Tofacitinib Monograph for Professionals". Drugs.com. Archived from the original on 28 September 2021. Retrieved 5 October 2021.
  3. ^ "10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 October 2020. Archived from the original on 27 July 2019. Retrieved 3 November 2020.
  4. ^ "Xeljanz 11 mg prolonged release tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 9 August 2020. Retrieved 3 November 2020.
  5. ^ "Xeljanz- tofacitinib tablet, film coated Xeljanz XR- tofacitinib tablet, film coated, extended release Xeljanz- tofacitinib solution". DailyMed. 2 October 2020. Archived from the original on 30 November 2020. Retrieved 3 November 2020.
  6. ^ a b c "Xeljanz EPAR". European Medicines Agency (EMA). Archived from the original on 28 October 2020. Retrieved 3 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ "Tofacitinib Use During Pregnancy | Drugs.com". Drugs.com. Archived from the original on 29 November 2020. Retrieved 5 October 2021.
  8. ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1168. ISBN 978-0-85711-369-6.
  9. ^ "Tofacitinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 5 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Tofacitinib&oldid=1152243779"